Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
Twelve to 22% of pediatric acute myeloid leukemia (AML) patients present with hyperleukocytosis, which is one of the main risk factors of early death due to its clinical complications: leukostasis, causing pulmonary or central nervous system injuries, tumor lysis syndrome, and disseminated intravasc...
Saved in:
Main Authors: | Franziska Schmidt (Author), Miriam Erlacher (Author), Charlotte Niemeyer (Author), Dirk Reinhardt (Author), Jan-Henning Klusmann (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3‐ITD AML
by: Daelynn R. Buelow, et al.
Published: (2019) -
Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
by: Sankaranarayan Kannan, et al.
Published: (2022) -
Treatment of three pediatric AML co-expressing NUP98-NSD1, FLT3-ITD, and WT1
by: Li Liu, et al.
Published: (2024) -
NUP98::NSD1 and FLT3/ITD co-expression is an independent predictor of poor prognosis in pediatric AML patients
by: Jing-wen Wang, et al.
Published: (2024) -
The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease
by: Farhan Basit, et al.
Published: (2018)